Abrogation of histone deacetylases (HDACs) decreases survival of chronic myeloid leukemia cells: New insight into attenuating effects of the PI3K/c‐Myc axis on panobinostat cytotoxicity

Anti‐leukemic effect of PI3K inhibition on chronic myeloid leukemia (CML) cells: shedding new light on the mitigating effect of c‐Myc and autophagy on BKM120 cytotoxicity

(2020) Reza Shiri Heris et al.   CELL BIOLOGY INTERNATIONAL

Pan-HDAC inhibitor panobinostat, as a single agent or in combination with PI3K inhibitor, induces apoptosis in APL cells: an emerging approach to overcome MSC-induced resistance

(2020) Mohammad Mosleh et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Anti-leukemic effects of histone deacetylase (HDAC) inhibition in acute lymphoblastic leukemia (ALL) cells: Shedding light on mitigating effects of NF-κB and autophagy on panobinostat cytotoxicity

(2020) Mahdieh Mehrpouri et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Synergistic effects of BKM120 and panobinostat on pre-B acute lymphoblastic cells: an emerging perspective for the simultaneous inhibition of PI3K and HDACs

(2020) Mahdieh Mehrpouri et al.   JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION

Histone Deacetylase Inhibition with Panobinostat Combined with Intensive Induction Chemotherapy in Older Patients with Acute Myeloid Leukemia: Phase I Study Results

(2019) Matthew J. Wieduwilt et al.   CLINICAL CANCER RESEARCH

Histone Deacetylases (HDACs) in gastric cancer: An update of their emerging prognostic and therapeutic role

(2019) Dimitrios Schizas et al.   CURRENT MEDICINAL CHEMISTRY

Epigenetic Reprogramming and Emerging Epigenetic Therapies in CML

(2019) Jane Bugler et al.   Frontiers in Cell and Developmental Biology

Synergistic Effects of PI3K and c-Myc Co-targeting in Acute Leukemia: Shedding New Light on Resistance to Selective PI3K-δ Inhibitor CAL-101

(2019) Niknam Riyahi et al.   CANCER INVESTIGATION

Targeting Epigenetics in Cancer

(2018) Richard L. Bennett et al.   Annual Review of Pharmacology and Toxicology

Antileukemic effects of neurokinin-1 receptor inhibition on hematologic malignant cells

(2018) Samaneh Bayati et al.   ANTI-CANCER DRUGS

Pan-HDAC inhibition by panobinostat mediates chemosensitization to carboplatin in non-small cell lung cancer via attenuation of EGFR signaling

(2018) Lingzhi Wang et al.   CANCER LETTERS

Epigenetic interplay between immune, stromal and cancer cells in the tumor microenvironment

(2018) Antonio Garcia-Gomez et al.   CLINICAL IMMUNOLOGY

Histone Deacetylase Inhibitors in Cancer Therapy

(2018) Yijie Sun et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Anticancer effect of pan-PI3K inhibitor on multiple myeloma cells: Shedding new light on the mechanisms involved in BKM120 resistance

(2018) Ava Safaroghli-Azar et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Panobinostat monotherapy and combination therapy in patients with acute myeloid leukemia: results from two clinical trials

(2017) Richard F. Schlenk et al.   HAEMATOLOGICA

A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts

(2017) G Garcia-Manero et al.   LEUKEMIA

Chemoresistance in cancer cells: exosomes as potential regulators of therapeutic tumor heterogeneity

(2017) Aman Sharma   Nanomedicine

Histone deacetylase inhibitors vorinostat and panobinostat induce G1 cell cycle arrest and apoptosis in multidrug resistant sarcoma cell lines

(2017) Eva Bernhart et al.   Oncotarget

PI3K/mTOR dual inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A synergistically exert anti-tumor activity in breast cancer

(2017) Liyan Chen et al.   Oncotarget

Panobinostat monotherapy and combination therapy in patients with acute myeloid leukemia: results from two clinical trials

(2017) Richard F. Schlenk et al.   HAEMATOLOGICA

A Novel Indication for Panobinostat as a Senolytic Drug in NSCLC and HNSCC

(2017) Leleesha Samaraweera et al.   Scientific Reports

Panobinostat induces apoptosis via production of reactive oxygen species and synergizes with topoisomerase inhibitors in cervical cancer cells

(2016) Lubna Wasim et al.   BIOMEDICINE & PHARMACOTHERAPY

The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer

(2016) Øystein Helland et al.   PLoS One

The BCR-ABL/NF-κB signal transduction network: a long lasting relationship in Philadelphia positive Leukemias

(2016) Giovanna Carrà et al.   Oncotarget

Panobinostat: First Global Approval

(2015) Karly P. Garnock-Jones   DRUGS

Drug Resistance in Cancer: An Overview

(2014) Genevieve Housman et al.   Cancers

Histone deacetylase inhibitors induce apoptosis in myeloid leukemia by suppressing autophagy

(2013) M V Stankov et al.   LEUKEMIA

Histone Deacetylase Regulation of ATM-Mediated DNA Damage Signaling

(2013) K. T. Thurn et al.   MOLECULAR CANCER THERAPEUTICS

Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy

(2011) Scott Thomas et al.   BREAST CANCER RESEARCH AND TREATMENT

research paper: Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia

(2010) Daniel Antunes Moreno et al.   BRITISH JOURNAL OF HAEMATOLOGY

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity

(2010) Amie S. Corbin et al.   JOURNAL OF CLINICAL INVESTIGATION

Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma

(2010) Sundar Jagannath et al.   LEUKEMIA RESEARCH

Proteasome proteolytic profile is linked to Bcr-Abl expression

(2009) Lisa J. Crawford et al.   EXPERIMENTAL HEMATOLOGY